Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia
The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by University of Malaya.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
University of Malaya
Collaborator:
Malaysian Society of Anaesthesiologists
Information provided by:
University of Malaya
ClinicalTrials.gov Identifier:
NCT01371968
First received: May 4, 2011
Last updated: June 10, 2011
Last verified: June 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study aims to determine the optimal dose of alfentanil in suppressing the airway reflexes during supreme LMA removal in anaesthetized adult.
| Condition | Intervention |
|---|---|
|
Airway Response |
Drug: alfentanil |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Pharmacokinetics Study Intervention Model: Single Group Assignment Masking: Single Blind (Outcomes Assessor) |
| Official Title: | Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia |
Resource links provided by NLM:
Further study details as provided by University of Malaya:
Primary Outcome Measures:
- Optimal dose of alfentanil for successful LMA removal in spontaneously breathing anaesthetized adults [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Nunber of patient with airway complication [ Time Frame: after administration of alfentanil and within 1 min of LMA removal ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 30 |
| Study Start Date: | February 2011 |
| Estimated Study Completion Date: | November 2011 |
| Estimated Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: alfentanil
patient will received a dose of alfentanil in which the dose of alfentanil is determined by response of previously tested patient using Dixon up and down methods
|
Drug: alfentanil
Alfentanil is administered intravenously at the end of surgery.
Other Name: Rapifen
|
Detailed Description:
The removal of LMA may be associated with coughing, biting, agitation and airway complication such as laryngospasm. Thus it is advisable to remove the LMA when the patient is breathing spontaneously and when the airway reflexes are still depressed. A number of techniques have been used to prevent this adverse emergence phenomenon, such as removing the tube while the patient is in deep plane of anaesthesia or administration of local anaesthetic and intravenous opioids
The administration of intravenous opioids before emergence may be useful for preventing cough, agitation and hemodynamic response. Alfentanyl is proven to suppress cough and agitation during the endotracheal tube emergence. However, its use in suppressing cough in LMA patient has not been evaluated.
Eligibility| Ages Eligible for Study: | 18 Years to 49 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- ASA I and II patients
- Age 18 to 49 years old
- Minor elective day care surgery (> 20 minute and less than 2 hours) which require local anaesthetic infiltration and does not require use of long acting opioids.
Exclusion Criteria:
- Potential difficult airway
- Reactive airway disease or sign and symptoms of upper respiratory tract infection.
- History of cardiac, pulmonary and renal diseases
- Body Mass Index > 30 kgm2.
- Risk of aspiration.
- Poor dentition with high risk of damage.
- Patient refusal.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01371968
Contacts
| Contact: Lee Chew Kiok, MBBS | 0162737229 | cklee1127@yahoo.com |
| Contact: Wang Chew Yin | 0192340232 | wangcy1836@gmail.com |
Locations
| Malaysia | |
| University Malaya Medical Centre | Recruiting |
| Lembah Pantai, Kuala Lumpur, Malaysia, 59100 | |
| Contact: Lee Chew Kiok, MBBS 0162737229 cklee1127@yahoo.com | |
| Contact: Wang Chew Yin 0192340232 wangcy1836@gmail.com | |
| Principal Investigator: Lee Chew Kiok, MBBS | |
Sponsors and Collaborators
University of Malaya
Malaysian Society of Anaesthesiologists
Investigators
| Principal Investigator: | Lee Chew Kiok, MBBS | Department of Anaesthesiogy, UMMC. |
More Information
No publications provided
| Responsible Party: | Dr Lee Chew Kiok, University Malaya Medical centre |
| ClinicalTrials.gov Identifier: | NCT01371968 History of Changes |
| Other Study ID Numbers: | Alfentanil LMA |
| Study First Received: | May 4, 2011 |
| Last Updated: | June 10, 2011 |
| Health Authority: | Malaysia: Ministry of Health |
Keywords provided by University of Malaya:
|
Alfentanil optimal dose laryngeal mask airway |
Additional relevant MeSH terms:
|
Alfentanil Anesthetics Desflurane Narcotics Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Analgesics |
Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses Anesthetics, Intravenous Anesthetics, General Analgesics, Opioid Anesthetics, Inhalation |
ClinicalTrials.gov processed this record on June 17, 2013